Bausch Health Companies Inc.

Company Snapshot

Founded: 1959
Entity Type: Public
Employees: 20,700
Region: U.S. and Puerto Rico
Revenue: $9,625.0 Millions
Revenue Year: 2024
Segment: Salix
Headquarter: Quebec, Canada
Key Geographics: U.S., Puerto Rico, China, Canada, U.K., Spain, Italy, Mexico, Poland, France, Japan, Germany, Russia, South Korea
Corporate Address: 2150 St. Elzéar Blvd. West, Laval, Québec, H7L 4A8 Canada Tel. +1-514-744-6792 www.bauschhealth.com

Company Overview

Bausch Health Companies Inc. is a globally diversified pharmaceutical company that develops, manufactures, and markets products, primarily in gastroenterology, neurology, dermatology, and international pharmaceuticals. The company produces and markets a broad range of branded and generic drugs and over-the-counter (OTC) products directly or indirectly in more than 90 countries and regions, including the United States, Canada, Europe, the Middle East, Africa, Asia Pacific, and Latin America.

Financial Highlights (FY 2024)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Bausch Health Companies Inc. In Reports

Global Pharmaceutical Drugs Industry: Competitive Landscape 2023

BCC Research Report: Dive into pharmaceutical drugs market dynamics, competitive intelligence, and regional trends are well-researched and analyzed in this report.

Medical Aesthetic Devices: Technologies and Global Markets

BCC Research Report: Dive into medical aesthetic devices market market estimates, data is provided for 2021 and 2022 as historical years, 2023 as the base year, and forecasts extend through 2029.

Global Myasthenia Gravis Treatment Market: Forecast and Trends

BCC Research Market Report says global market for myasthenia gravis treatment is estimated to increase from $1.3 billion in 2023 to reach $2.2 billion by 2028, at a CAGR of 10.5%.

Company's Business Segments

  • Salix : The Salix segment consists of sales in the U.S. of GI products like Sales of Xifaxan, Others.
  • International : The International segment consists of sales, except for sales of Bausch + Lomb products, Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded Pharmaceutical products, branded Generic pharmaceutical products, OTC products.
  • Solta Medical : The Solta Medical segment consists of global Solta Medical Aesthetic medical device sales.
  • Diversified : The Diversified segment consists of sales in the U.S. of Pharmaceutical products in Neurology, certain other Therapeutic classes, Dermatology products, Generic pharmaceutical products, Dentistry products.
  • Bausch + Lomb : The Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, Surgical, Pharmaceuticals products.

Applications/End User Industries

  • Vision Care
  • Surgical
  • Pharmaceuticals
  • Neurology
  • Medical Devices
  • Gastroenterology
  • Hepatology
  • Dermatology
  • Generic Pharmaceutical
  • Dentistry
  • Over The Counter
  • Healthcare